Kevin

106 days ago

Video: Skinbiotherapeutics and the scale of the revenue miss, pre placing

A helpful reader supplies a video of a man that certain commentators, habitually resident a long way up a Tyneside rectum, say that I really should respect and not refer to as the bearded, troughing, useless Geordie poltroon. That is to say Skinbiotherapeutics (SBTX) CEO Stuart Ashman. In it he discusses the forecasts published on July 7 by Singer analyst Karl “Kevin” Keegan.

---